Clinical Trials Logo

Neuroendocrine Carcinoma clinical trials

View clinical trials related to Neuroendocrine Carcinoma.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT02236910 Active, not recruiting - Clinical trials for Neuroendocrine Carcinoma

An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours

Start date: July 2014
Phase: Phase 2
Study type: Interventional

Lu-DOTA-TATE (Lutetium-177 octreotate) is a radiopharmaceutical that has been reported as being effective in controlling symptoms and increase quality of life; induce stable disease and extend progression free survival; induce a (good) partial remission and induce a complete remission in patients with a somatostatin receptor positive tumour. The purpose of this study is to assess the efficacy of Lu-DOTA-TATE by measuring progression free survival and overall survival. This study will also asses the safety of Lu-DOTA-TATE, and the quality of life of the patients treated with Lu-DOTA-TATE.

NCT ID: NCT01396382 Active, not recruiting - Clinical trials for Neuroendocrine Carcinoma

68Ga-DOTATATE PET Scan in Neuroendocrine Cancer

68Ga
Start date: August 2011
Phase: Phase 1/Phase 2
Study type: Interventional

Neuroendocrine cancer is an unusual disease and often goes undetected by routine imaging. The 68Ga-DOTATATE PET scan is a new generation of scans that might have improved sensitivity and resolution specifically for neuroendocrine tumors. The investigators will scan people with this cancer and compare it to other conventional imaging methods to see if it improves patient care.